phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthaseGenealiases: ADE2 · ADE2H1 · AIRC · PAICSD · PAIS
Q-omics provides the consensus-scored PAICS profile across patient tissues and cancer cell-line models. PAICS expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PAICS is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, PAICS protein abundance shows 28,619 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, BLCA, and LSCC as cancer lineages where PAICS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAICS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAICS survival associations across molecular data types. PAICS RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAICS RNA expression–survival associations across cancer types. High PAICS expression shows unfavorable associations in KIRP, CESC, KICH, LUAD and LIHC, but favorable associations in READ. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PAICS RNA expression.
This table summarizes PAICS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 8. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PAICS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAICS shows higher tumor expression in BLCA, LUAD, COAD, HNSC, KIRC and LUSC. The BLCA box plot shows higher PAICS RNA expression in tumor versus normal tissue (log2 FC = +1.208, t-test p < 0.001).
This table shows molecular features associated with PAICS in patient tissues and cancer cell lines. In patient samples, PAICS shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PAICS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
